Citations

Clear

107 citation(s) found for "Scheithauer, Bernd".

The Effects of Dextrose Infusion and Head Position on Neurologic Outcome after Complete Cerebral Ischemia in Primates
Lanier, William L. , Stangland, Kenneth J., Scheithauer, Bernd W., Milde, James H., Michenfelder, John D.

Mayo Clinic

Anesthesiology | September 28, 2006 | Volume: 66 | Issue: 1 | Pages: 39-48

10.1097/00000542-198701000-00008 | PMID 3800033 Get It

Nimodipine Improves Outcome when Given after Complete Cerebral Ischemia in Primates
Steen, Petter Andreas, Gisvold, Sven Erik, Milde, James H., Newberg, Leslie A., Scheithauer, Bernd W., Lanier, William L. , Michenfelder, John D.

Mayo Clinic

Anesthesiology | September 26, 2006 | Volume: 62 | Issue: 4 | Pages: 406-414

10.1097/00000542-198504000-00007 | PMID 3985399 Get It

Phase III Trial of Carmustine and Cisplatin Compared With Carmustine Alone and Standard Radiation Therapy or Accelerated Radiation Therapy in Patients With Glioblastoma Multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group
Buckner, Jan C. , Michalak, John C., Burton, Gary V., Cascino, Terrence L., Schomberg, Paula J., Hawkins, Roland B., Scheithauer, Bernd W., Marks, Randolph S., OʼFallon, Judith R., Ballman, Karla V. , Sandler, Howard M.

Mayo Clinic

Journal of Clinical Oncology | August 18, 2006 | Volume: 24 | Issue: 24 | Pages: 3871-3879

10.1200/jco.2005.04.6979 | PMID 16921039 Get It

Purpose In patients with newly diagnosed glioblastoma multiforme, to determine whether cisplatin plus carmustine (BCNU) administered before and concurrently with radiation therapy (RT) improves survival compared with BCNU and RT and whether survival using accelerated RT (ART) is equivalent to survival using standard RT (SRT). Patients and Methods After surgery, patients were stratified by age, performance score, extent of surgical resection, and histology (glioblastoma v gliosarcoma) and then randomly assigned to arm A (BCNU plus SRT), arm B (BCNU plus ART), arm C (cisplatin plus BCNU plus SRT), or arm D (cisplatin plus BCNU plus ART). Results Four hundred fifty-one patients were randomly assigned, and 401 were eligible. Frequent toxicities included myelosuppression, vomiting, sensory neuropathy, and ototoxicity and were worse with cisplatin. There was no difference in toxicity between SRT and ART. Median survival times and 2-year survival rates for patients who received BCNU plus RT (arms A and B) compared with cisplatin, BCNU, and RT (arms C and D) were 10.1 v 11.5 months, respectively, and 11.5% v 13.7%, respectively (P = .19). Median survival times and 2-year survival rates for patients who received SRT (arms A and C) compared with ART (arms B and D) were 11.2 v 10.5 months, respectively, and 13.8% v 11.4%, respectively (P = .33). Conclusion Cisplatin administered concurrently with BCNU and RT resulted in more toxicity but provided no significant improvement in survival. SRT and ART produced similar toxicity and survival.
Primary Melanocytic Tumor of the Cerebellopontine Angle Mimickinga Vestibular Schwannoma
Piedra, Mark, Scheithauer, Bernd W., Driscoll, Colin L. W., Link, Michael J.

Mayo Clinic

Neurosurgery | July 6, 2006 | Volume: 59 | Issue: 1 | Pages: E206-E206

10.1227/01.neu.0000219236.48886.44 | PMID 16823290 Get It

Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402
Cairncross, Gregory, Shaw, Edward , Jenkins, Robert B. , Scheithauer, Bernd W., Brachman, David, Buckner, Jan C. , Fink, Karen, Souhami, Luís, Laperierre, Normand, Mehta, Minesh P. , Curran, Walter J. , Berkey, Brian A. , Mehta, Minesh P

Mayo Clinic

Journal of Clinical Oncology | June 16, 2006 | Volume: 24 | Issue: 18 | Pages: 2707-2714

10.1200/jco.2005.04.3414 | PMID 16782910 Get It

Purpose Anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) are treated with surgery and radiotherapy (RT) at diagnosis, but they also respond to procarbazine, lomustine, and vincristine (PCV), raising the possibility that early chemotherapy will improve survival. Furthermore, better outcomes in AO have been associated with 1p and 19q allelic loss. Patients and Methods Patients with AO and AOA were randomly assigned to PCV chemotherapy followed by RT versus postoperative RT alone. The primary end point was overall survival. The status of 1p and 19q alleles was assessed by fluorescence in situ hybridization. Results Two hundred eighty-nine eligible patients were randomly assigned to either PCV plus RT (n = 147) or RT alone (n = 142). At progression, 80% of patients randomly assigned to RT had chemotherapy. With 3-year follow-up on most patients, the median survival times were similar (4.9 years after PCV plus RT v 4.7 years after RT alone; hazard ratio [HR] = 0.90; 95% CI, 0.66 to 1.24; P = .26). Progression-free survival time favored PCV plus RT (2.6 years v 1.7 years for RT alone; HR = 0.69; 95% CI, 0.52 to 0.91; P = .004), but 65% of patients experienced grade 3 or 4 toxicity, and one patient died. Patients with tumors lacking 1p and 19q (46%) compared with tumors not lacking 1p and 19q had longer median survival times (> 7 v 2.8 years, respectively; P ≤ .001); longer progression-free survival was most apparent in this subset. Conclusion For patients with AO and AOA, PCV plus RT does not prolong survival. Longer progression-free survival after PCV plus RT is associated with significant toxicity. Tumors lacking 1p and 19q alleles are less aggressive or more responsive or both.
Deep Sylvian Fissure Chordoid Meningioma: Case Report
McIver, Jon I., Scheithauer, Bernd W., Atkinson, John L. D.

Mayo Clinic

Neurosurgery | November 11, 2005 | Volume: 57 | Issue: 5 | Pages: E1064-E1064

10.1227/01.neu.0000180038.12168.ca | PMID 16284544 Get It

Neurocytoma of the VIIIth Cranial Nerve: Case Report
Öngürü, Önder, Kurtkaya-Yapıcıer, Özlem, Scheithauer, Bernd W., Burger, Peter C. , Mann, Sherrie J., Harvey, Steven A., Luetmer, Patrick H.

Mayo Clinic

Neurosurgery | November 11, 2005 | Volume: 57 | Issue: 5 | Pages: E1065-E1065

10.1227/01.neu.0000179981.62074.b1 | PMID 16284545 Get It

Effects of DNA Methylation on Galectin-3 Expression in Pituitary Tumors
Ruebel, Katharina H., Jin, Long , Qian, Xiang , Scheithauer, Bernd W., Kovács, Kálmán, Nakamura, Nobuki, Zhang, Heyu , Raz, Avraham, Lloyd, Ricardo V.

Mayo Clinic

Cancer Research | September 15, 2005 | Volume: 65 | Issue: 4 | Pages: 1136-1140

10.1158/0008-5472.can-04-3578 | PMID 15734994 Get It

Abstract Galectin-3 (Gal-3), a β-galactoside-binding protein is expressed in a specific cell–type manner in pituitary tumors. Here we questioned the mechanism of Gal-3 expression in pituitary tumors, by using methylation-specific PCR and DNA sequence analyses to analyze the methylation status of the promoter region of the LGALS3 gene. DNA analysis of a human pituitary tumor, breast carcinoma cell lines, and thyroid carcinoma cell lines showed that in cells expressing Gal-3 protein, the LGALS3 gene was unmethylated, whereas in Gal-3 null cells, the promoter of the LGALS3 gene was methylated. Treatment of cells with 30 μmol/L 5-aza-2′-deoxycytidine induced Gal-3 mRNA and protein expression. Among pituitary tumors, 30% (7/23), mainly in follicle-stimulating hormone/luteinizing hormone–producing (38%) and null cell (57%) adenomas, the promoter of the LGALS3 was found to be methylated and silenced, although prolactin- and adrenocorticotropic hormone–producing tumors, which were unmethylated, expressed the Gal-3 protein. These results show for the first time that Gal-3 expression is regulated in part by promoter methylation in pituitary as well as in other tumors. Because it is functionally involved in cancer progression and metastasis, Gal-3 may serve as a possible therapeutic target in the treatment of pituitary tumors.
Clinicopathologic and Genetic Profile of Intracranial Marginal Zone Lymphoma: A Primary Low-Grade CNS Lymphoma That Mimics Meningioma
Judkins, Alexander R. , Schwalb, Jason M. , Yachnis, Anthony T. , Burger, Peter C. , Scheithauer, Bernd W., Perry, Arie , Tu, Pang‐Hsien , Giannini, Caterina , Burack, Richard , O’Neill, Brian Patrick , Perry, Arie

Mayo Clinic

Journal of Clinical Oncology | July 12, 2005 | Volume: 23 | Issue: 24 | Pages: 5718-5727

10.1200/jco.2005.17.624 | PMID 16009945 Get It

PurposeAlthough rare overall, marginal zone B-cell lymphoma (MZBCL) is the most common primary low-grade CNS lymphoma reported in the literature. The aim of this study is to elucidate the biology and genetic features of this unusual tumor.Patients and MethodsFifteen CNS MZBCLs were studied clinically, pathologically, and genetically, including fluorescent in situ hybridization analyses with commercially available MALT1 and IgH break-apart and centromere 3, 7, 12, and 18 probes.ResultsCNS MZBCLs preferentially affect middle-aged women (female-to-male ratio, 4:1), with 93% presenting as dural-based masses mimicking meningioma. Ten patients with 1 to 7.6 years of follow-up after diagnosis showed no evidence of disease after radiation and/or chemotherapy. Like MZBCLs outside of the CNS, they consisted of CD20+, CD3−small B lymphocytes with varying degrees of plasmacytic differentiation and predominantly κ light-chain restriction (78%). Lymphoid follicles with follicular colonization were seen in three patients and deposition of amyloid was noted in samples from two patients, one of which was tumefactive. Neither Bcl-6 protein nor Epstein-Barr virus–encoded RNA was expressed. Trisomy 3 was detected in six of 12 patients, with no rearrangements of MALT1 or IgH and no trisomies of 7, 12, or 18 detected.ConclusionOur data suggest that intracranial MZBCL is an indolent primary CNS lymphoma that typically presents as a meningioma-like dural-based mass. Trisomy 3, but not MALT1 or IgH translocation, is a common genetic abnormality that may contribute to the pathogenesis of this CNS lymphoma.
Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
Buckner, Jan C. , Maurer, Matthew J. , Kreisberg, Jeffrey I., Boni, Joseph , Peralba, Josep Maria, Jenkins, Robert B. , Dakhil, Shaker R. , Morton, Roscoe F., Jaeckle, Kurt A. , Scheithauer, Bernd W., Dancey, Janet, Hidalgo, Manuel , Walsh, Daniel J. , Galanis, Evanthia , Ballman, Karla V. , Maurer, Matthew

Mayo Clinic

Journal of Clinical Oncology | July 6, 2005 | Volume: 23 | Issue: 23 | Pages: 5294-5304

10.1200/jco.2005.23.622 | PMID 15998902 Get It

Background Temsirolimus (CCI-779) is a small-molecule inhibitor of the mammalian target of rapamycin (mTOR) and represents a rational therapeutic target against glioblastoma multiforme (GBM). Methods Recurrent GBM patients with ≤ 1 chemotherapy regimen for progressive disease were eligible. Temsirolimus was administered in a 250-mg intravenous dose weekly. Results Sixty-five patients were treated. The incidence of grade 3 or higher nonhematologic toxicity was 51%, and consisted mostly of hypercholesterolemia (11%), hypertriglyceridemia (8%), and hyperglycemia (8%). Grade 3 hematologic toxicity was observed in 11% of patients. Temsirolimus peak concentration (Cmax), and sirolimus Cmax and area under the concentration-time curve were decreased in patients receiving p450 enzyme–inducing anticonvulsants (EIACs) by 73%, 47%, and 50%, respectively, but were still within the therapeutic range of preclinical models. Twenty patients (36%) had evidence of improvement in neuroimaging, consisting of decrease in T2 signal abnormality +/− decrease in T1 gadolinium enhancement, on stable or reduced steroid doses. Progression-free survival at 6 months was 7.8% and median overall survival was 4.4 months. Median time to progression (TTP) for all patients was 2.3 months and was significantly longer for responders (5.4 months) versus nonresponders (1.9 months). Development of grade 2 or higher hyperlipidemia in the first two treatment cycles was associated with a higher percentage of radiographic response (71% v 31%; P = .04). Significant correlation was observed between radiographic improvement and high levels of phosphorylated p70s6 kinase in baseline tumor samples (P = .04). Conclusion Temsirolimus is well tolerated in recurrent GBM patients. Despite the effect of EIACs on temsirolimus metabolism, therapeutic levels were achieved. Radiographic improvement was observed in 36% of temsirolimus–treated patients, and was associated with significantly longer TTP. High levels of phosphorylated p70s6 kinase in baseline tumor samples appear to predict a patient population more likely to derive benefit from treatment. These findings should be validated in other studies of mTOR inhibitors.